A5081788616- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Chemical Synthesis and Analysis
- Multiple Myeloma Research and Treatments
- Medical Imaging Techniques and Applications
- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Mass Spectrometry Techniques and Applications
- Neuroendocrine Tumor Research Advances
- Immunotherapy and Immune Responses
- Advanced NMR Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Advanced MRI Techniques and Applications
- Neuroblastoma Research and Treatments
- Electron Spin Resonance Studies
- Atomic and Subatomic Physics Research
- Bladder and Urothelial Cancer Treatments
- Orthopedic Infections and Treatments
- Thyroid Cancer Diagnosis and Treatment
- Cancer Research and Treatments
- Receptor Mechanisms and Signaling
University of California, San Francisco
2016-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2019-2025
University of California System
2015-2024
Berry (United States)
2021-2022
University of California San Francisco Medical Center
2019
Laboratoire d’Imagerie Biomédicale
2018
University of Hawaiʻi at Mānoa
2017
University of Alberta
2017
Rockefeller University
2001-2011
Imaging Center
2008
In retrospective studies, 68Ga-PSMA-11 positron emission tomographic (PET) imaging improves detection of biochemically recurrent prostate cancer compared with conventional imaging.To assess PET accuracy in a prospective multicenter trial.In this single-arm trial conducted at University California, San Francisco and Los Angeles, 635 patients after prostatectomy (n = 262, 41%), radiation therapy 169, 27%), or both 204, 32%) underwent PET. Presence was recorded by 3 blinded readers on...
Purpose To develop and validate a deep learning algorithm that predicts the final diagnosis of Alzheimer disease (AD), mild cognitive impairment, or neither at fluorine 18 (
The mechanisms of postacute medical conditions and unexplained symptoms after SARS-CoV-2 infection [Long Covid (LC)] are incompletely understood. There is growing evidence that viral persistence, immune dysregulation, T cell dysfunction may play major roles. We performed whole-body positron emission tomography imaging in a well-characterized cohort 24 participants at time points ranging from 27 to 910 days acute using the radiopharmaceutical agent [
Prostate-specific membrane antigen (PSMA) ligand PET induces management changes in patients with prostate cancer. We aim to better characterize the impact of <sup>68</sup>Ga-PSMA-11 (<sup>68</sup>Ga-PSMA PET) on recurrent cancer a large prospective cohort. <b>Methods:</b> report after <sup>68</sup>Ga-PSMA PET, secondary endpoint multicenter trial men biochemical recurrence Pre-PET (Q1), post-PET (Q2), and posttreatment (Q3) questionnaires were sent referring physicians recording site...
ABSTRACT The etiologic mechanisms of post-acute medical morbidities and unexplained symptoms (Long COVID) following SARS-CoV-2 infection are incompletely understood. There is growing evidence that viral persistence immune dysregulation may play a major role. We performed whole-body positron emission tomography (PET) imaging in cohort 24 participants at time points ranging from 27 to 910 days acute using novel radiopharmaceutical agent, [ 18 F]F-AraG, highly selective tracer allows for...
Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression developed an antibody-drug conjugate immunoPET agent based on YS5 antibody, which targets a tumor-selective epitope. Here, we present preparation, preclinical efficacy, toxicity evaluation [225Ac]DOTA-YS5, radioimmunotherapy antibody.
Molecularly targeted radionuclide therapies (TRTs) struggle with balancing efficacy and safety, as current strategies to increase tumor absorption often alter drug pharmacokinetics prolong circulation normal tissue irradiation. Here we report the first covalent protein TRT, which, through reacting target irreversibly, increases radioactive dose without altering drug's pharmacokinetic profile or biodistribution. Through genetic code expansion, engineered a latent bioreactive amino acid into...
Ac, a long-lived α-emitter with half-life of 9.92 days, has garnered significant attention as therapeutic radionuclide when coupled monoclonal antibodies and other targeting vectors. Nevertheless, its clinical utility been hampered by potential off-target toxicity, lack optimized chelators for
Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety cancers, has become target novel PET tracers. The purpose this report is to evaluate imaging characteristics <sup>68</sup>Ga-FAP-2286, present first—to our knowledge—dosimetry analysis date, and compare agent with <sup>18</sup>F-FDG FAPI compounds. <b>Methods:</b> Patients were administered 219 ± 43 MBq <sup>68</sup>Ga-FAP-2286 scanned after 60 min. Uptake was measured up 5 lesions per patient within...
Occult bacterial infections represent a worldwide health problem. Differentiating active infection from sterile inflammation can be difficult using current imaging tools. Present clinically viable methodologies either detect morphologic changes (CT/ MR), recruitment of immune cells (111In-WBC SPECT), or enhanced glycolytic flux seen in inflammatory (18F-FDG PET). However, these strategies are often inadequate to and not specific for living bacteria. Recent approaches have taken advantage key...
Imaging studies are frequently used to support the clinical diagnosis of infection. These techniques include computed tomography (CT) and magnetic resonance imaging (MRI) for structural information single photon emission (SPECT) or positron (PET) metabolic data. However, frequently, there is significant overlap in appearance infectious noninfectious entities using these tools. To address this concern, recent approaches have targeted bacteria-specific pathways. For example, radiolabeled...
Incorporation of d-amino acids into peptidoglycan is a unique metabolic feature bacteria. Since are not substrates in most mammalian tissues, this difference can be exploited to detect living bacteria vivo. Given the prevalence d-alanine muropeptides, as well its role several antibiotic mechanisms, we targeted amino acid for positron emission tomography (PET) radiotracer development. d-[3-11C]Alanine and dipeptide d-[3-11C]alanyl-d-alanine were synthesized via asymmetric alkylation...
A major obstacle to achieving long-term antiretroviral (ART) free remission or functional cure of HIV infection is the presence persistently infected cells that establish a long-lived viral reservoir. largely resides in anatomical regions are inaccessible routine sampling, however, and non-invasive methods understand longitudinal tissue-wide burden persistence urgently needed. Positron emission tomography (PET) imaging promising strategy identify characterize HIV. Here, we assess efficacy...
Non-invasive imaging is a key clinical tool for detection and treatment monitoring of infections. Existing techniques are frequently unable to distinguish infection from tumors or sterile inflammation. This challenge well-illustrated by prosthetic joint infections that often complicate replacements. D-methyl-11C-methionine (D-11C-Met) new bacteria-specific PET radiotracer, based on an amino acid D-enantiomer, rapidly incorporated into the bacterial cell wall. In this manuscript, we describe...
<sup>225</sup>Ac-targeted α-radiotherapy is a promising approach to treating malignancies, including prostate cancer. However, α-emitting isotopes are difficult image because of low administered activities and fraction suitable γ-emissions. The in vivo generator <sup>134</sup>Ce/<sup>134</sup>La has been proposed as potential PET imaging surrogate for the therapeutic nuclides <sup>225</sup>Ac <sup>227</sup>Th. In this report, we detail efficient radiolabeling methods using...
Abstract We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small neuroendocrine subtypes of metastatic castration resistant (mCRPC), discovered an internalizing human monoclonal antibody YS5 binds to tumor selective epitope, developed microtubule inhibitor-based drug conjugate is multi-center phase I trial for mCRPC (NCT03575819). Here we report the development CD46-targeted alpha therapy based on...
The tumor uptake of large non-targeted nanocarriers primarily occurs through passive extravasation, known as the enhanced permeability and retention (EPR) effect. Prior studies demonstrated improved 4-arm 40 kDa star polyethylene glycol (StarPEG) polymers for cancer imaging by adding prostate-specific membrane antigen (PSMA) targeting small molecule ligands. To test PSMA-targeted delivery therapeutic efficacy, StarPEG nanodrugs with/without three copies PSMA-targeting ligands, ACUPA, are...
Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa).Actinium-225 ( 225 Ac), potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases sustained antitumor responses.The development radiolabeling techniques involving EDTA, DOTA, DOTPA, Macropa chelators laid groundwork advancements this field.At forefront clinical trials with Ac PCa are PSMA-targeted TAT agents, notably [...
This study applied a dual-agent, 13C-pyruvate and 13C-urea, hyperpolarized 13C magnetic resonance spectroscopic imaging (MRSI) multi-parametric (mp) 1H (MRI) approach in the transgenic adenocarcinoma of mouse prostate (TRAMP) model to investigate changes tumor perfusion lactate metabolism during cancer development, progression metastases, after dehydrogenase-A (LDHA) knock-out. An increased Warburg effect, as measured by an elevated (HP) Lactate/Pyruvate (Lac/Pyr) ratio, associated Ldha...
Boron neutron capture therapy (BNCT) is a therapeutic modality which has been used for the treatment of cancers, including brain and head neck tumors. For effective via BNCT, efficient selective delivery high boron dose to cancer cells needed. Prostate-specific membrane antigen (PSMA) target prostate imaging drug delivery. In this study, we conjugated boronic acid or carborane functional groups well-established PSMA inhibitor scaffold deliver tumor xenograft models. Eight boron-containing...